Semaphorin 3C as a Therapeutic Target in Prostate and Other Cancers

• Published in: International journal of molecular sciences Vol. 20; no. 3; p. 774
• Main Authors: Hui, Daniel H.F., Tam, Kevin J., Jiao, Ivy Z.F., Ong, Christopher J.
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 12.02.2019; MDPI
• Subjects: Androgens; Animals; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Binding sites; Biology; Cell Proliferation - drug effects; Epidermal growth factor; Fibroblasts; Humans; Kinases; Male; Metastasis; Prostate - drug effects; Prostate cancer; Prostatic Neoplasms - drug therapy; Proteins; Review; Roles; Semaphorins - pharmacology; Semaphorins - therapeutic use; Transcription factors; cancer therapeutics; inhibitors; neuropilins; plexins; semaphorins; SEMA3C
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms20030774

The semaphorins represent a large family of signaling molecules with crucial roles in neuronal and cardiac development. While normal semaphorin function pertains largely to development, their involvement in malignancy is becoming increasingly evident. One member, Semaphorin 3C (SEMA3C), has been shown to drive a number of oncogenic programs, correlate inversely with cancer prognosis, and promote the progression of multiple different cancer types. This report surveys the body of knowledge surrounding SEMA3C as a therapeutic target in cancer. In particular, we summarize SEMA3C’s role as an autocrine andromedin in prostate cancer growth and survival and provide an overview of other cancer types that SEMA3C has been implicated in including pancreas, brain, breast, and stomach. We also propose molecular strategies that could potentially be deployed against SEMA3C as anticancer agents such as biologics, small molecules, monoclonal antibodies and antisense oligonucleotides. Finally, we discuss important considerations for the inhibition of SEMA3C as a cancer therapeutic agent.